At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 21 enrolled
Drug / intervention
Perampanel +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multicenter, Uncontrolled, Open-label Study to Evaluate the Safety and Tolerability of Intravenous Perampanel as Substitute for Oral Tablet in Subjects With Partial Onset Seizures (Including Secondarily Generalized Seizures) or Primary Generalized Tonic-clonic Seizures
In Brief
A Phase 2 clinical trial evaluating Perampanel for Epilepsy and Seizures. Completed, enrolled 21 participants across 13 sites.
Detailed Summary
The purpose of the study is to evaluate the safety and tolerability of perampanel administered as a 30-minute intravenous infusion after switching from oral tablets (8 to 12 milligrams per day \[mg/day\]) as an adjunctive therapy in participants with epilepsy with partial onset seizures (POS) (including secondarily generalized seizures) or primary generalized tonic-clonic (PGTC) seizures.
Study Details
Timeline
Phase 2CompletedFinished
20192020202120222023202420252026
First PostedNov 2018
Enrollment StartNov 2018
Primary CompletionDec 2019
TodayJul 2026
First PostedNov 27, 2018
Enrollment StartNov 27, 2018
Primary CompletionDec 10, 2019
TodayJul 2, 2026
Enrollment to primary: 1.0 yearsPosted 7.6 years ago
Interventions
Perampaneldrug
Oral tablets.
Perampaneldrug
Intravenous infusion.